Ipsen : Feedback CMD 2020 - Objectif : élargissement du portefeuille – OC : 89 €
>Hausse de la R&D et M&A - L’objectif du capital market day aura été, pour le nouveau CEO, de présenter ses initiatives stratégiques et les composantes de la trajectoire du groupe, d’ici à 2024.Le management d’Ipsen veut enrichir le pipeline en augmentant ses investissements en R&D (probablement autour de 20%+ à terme vs 15,5% en 2019), et en procédant à des acquisitions d’actifs (produits et technologies, licences…), avec, pour cela, une enveloppe estimée à 3 M...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.